Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice

Federico Giulietti, Andrea Filipponi, Giulia Rosettani, Piero Giordano, Corrado Iacoacci, Francesco Spannella, Riccardo Sarzani, Federico Giulietti, Andrea Filipponi, Giulia Rosettani, Piero Giordano, Corrado Iacoacci, Francesco Spannella, Riccardo Sarzani

Abstract

Tobacco use is one of the major public health concerns and it is the most preventable cause of morbidity and mortality worldwide. Smoking cessation reduces subsequent cardiovascular events and mortality. Smoking is a real chronic disorder characterized by the development of an addiction status mainly due to nicotine. This condition makes the smokers generally unable to quit smoking without help. Different strategies are available to treat smoking dependence that include both non-pharmacological (behavioral counselling) and pharmacological therapies. Currently, it is well accepted that smoking cessation drugs are effective and safe in real-world settings. Nicotine replacement therapy (NRT), varenicline, bupropion and cytisine are the main pharmacological strategies available for smoking cessation. Their efficacy and safety have been proved even in patients with chronic cardiovascular disease. Each of these drugs has peculiar characteristics and the clinician should customize the smoking cessation strategy based on currently available scientific evidence and patient's preference, paying particular attention to those patients having specific cardiovascular and psychiatric comorbidities. The present document aims to summarize the current viable pharmacological strategies for smoking cessation, also discussing the controversial issue regarding the use of alternative tobacco products, in order to provide useful practical indications to all physicians, mainly to those involved in cardiovascular prevention.

Keywords: Alternative tobacco products; Bupropion; Nicotine addiction; Nicotine replacement therapy; Smoking cessation; Varenicline.

Conflict of interest statement

The Authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Proposed flow-chart for smoking cessation

References

    1. Adams JM. Smoking cessation - progress, barriers, and new opportunities: the surgeon general's report on smoking cessation. JAMA. 2020. 10.1001/jama.2020.6647.
    1. Ward BWCT, Nugent CN, Schiller JS. Early release of selected estimates based on data from the 2015 National Health Interview Survey. Hyattsville: National Center for Health Statistics; 2016.
    1. Volpe M, Battistoni A, Gallo G, Rubattu S, Tocci G, Writing C, et al. Executive summary of the 2018 joint consensus document on Cardiovascular Disease Prevention in Italy. High Blood Pressure Cardiovasc Prevent Off J Italian Soc Hypertens. 2018;25(3):327–341.
    1. Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri MA, Morris PB, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2018;72(25):3332–3365.
    1. Collaborators USBoD. Mokdad AH, Ballestros K, Echko M, Glenn S, Olsen HE, et al. The state of US Health, 1990–2016: burden of diseases, injuries, and risk factors among US states. JAMA. 2018;319(14):1444–1472.
    1. Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717.
    1. Giudice R, Izzo R, Manzi MV, Pagnano G, Santoro M, Rao MA, et al. Lifestyle-related risk factors, smoking status and cardiovascular disease. High Blood Pressure Cardiovasc Prevent Off J Italian Soc Hypertens. 2012;19(2):85–92.
    1. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519.
    1. Ferri C. Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease. High Blood Pressure Cardiovasc Prevent Off J Italian Soc Hypertens. 2015;22(2):103–111.
    1. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;201(12):1557–1559.
    1. Jarvis MJ. Why people smoke. BMJ. 2004;328(7434):277–279.
    1. U.S. Department of Health and Human Services. Smoking Cessation. A report of the surgeon general. In: Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2020. . Accessed 19 June 2020.
    1. Picciotto MR, Kenny PJ. Molecular mechanisms underlying behaviors related to nicotine addiction. Cold Spring Harbor Perspect Med. 2013;3(1):a012112.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. Br J Addict. 1991;86(9):1119–1127.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict. 1989;84(7):791–799.
    1. Chassin L, Presson CC, Sherman SJ, Edwards DA. The natural history of cigarette smoking: predicting young-adult smoking outcomes from adolescent smoking patterns. Health Psychol Off J Div Health Psychol Am Psychol Assoc. 1990;9(6):701–716.
    1. Hughes JR. Motivating and helping smokers to stop smoking. J Gen Intern Med. 2003;18(12):1053–1057.
    1. World Health Organization. Toolkit for delivering the 5A’s and 5R’s brief tobacco interventions in primary care. 2014. . Accessed 5 Jun 2020.
    1. European Network for Smoking and Tobacco Prevention. ENSP Guidelines for treating tobacco dependence the comprehensive guide to the implementation of treatments and strategies to treat tobacco dependence. 2016. . Accessed 5 Jun 2020.
    1. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66(11):1253–1262.
    1. Smith SS, McCarthy DE, Japuntich SJ, Christiansen B, Piper ME, Jorenby DE, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med. 2009;169(22):2148–2155.
    1. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44(6):588–597.
    1. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Datab Syst Rev. 2013;5:CD009329.
    1. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med. 2011;171(8):770–777.
    1. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64–71.
    1. Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ. Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016;5(2):e002849.
    1. McClure JB, Swan GE, Catz SL, Jack L, Javitz H, McAfee T, et al. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat. 2010;38(4):394–402.
    1. Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology. 2009;14(3):384–392.
    1. Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. BMJ. 2015;2(350):h2388.
    1. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Internal Med. 2001;135(6):423–433.
    1. Hughes JR. Depression during tobacco abstinence. Nicotine Tobacco Res Off J Soc Res Nicotine Tobacco. 2007;9(4):443–446.
    1. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001;357(9268):1571–1575.
    1. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med. 2003;163(19):2337–2344.
    1. Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Internal Med. 2018;178(5):622–631.
    1. Tackett AE, Smith KM. Bupropion-induced angioedema. Am J Health-System Pharm AJHP Off J Am Soc Health-System Pharm. 2008;65(17):1627–1630.
    1. Kim CS, Choi JS, Bae EH, Kim SW. Hyponatremia associated with bupropion. Electrolyte Blood Pressure E & BP. 2011;9(1):23–26.
    1. Tutka P, Zatonski W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep PR. 2006;58(6):777–798.
    1. Walker N, Howe C, Glover M, McRobbie H, Barnes J, Nosa V, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med. 2014;371(25):2353–2362.
    1. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med. 2011;365(13):1193–1200.
    1. Società Italiana di Tabaccologia (SITAB). Linee guida per il trattamento della dipendenza da tabacco 2018. . Accessed 5 Jun 2020.
    1. Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Datab Syst Rev. 2000;4:CD002849.
    1. Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N. Antidepressants for smoking cessation. Cochrane Datab Syst Rev. 2020;4:CD000031.
    1. Phs Guideline Update Panel L, Staff Treating tobacco use and dependence: 2008 update US Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008;53(9):1217–1222.
    1. Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chronic Obstruct Pulmonary Disease. 2008;3(1):45–53.
    1. Glantz SA, Bareham DW. E-cigarettes: use, effects on smoking, risks, and policy implications. Annu Rev Public Health. 2018;1(39):215–235.
    1. Ratajczak A, Jankowski P, Strus P, Feleszko W. Heat not burn tobacco product—a new global trend: impact of heat-not-burn tobacco products on public health, a systematic review. Int J Environ Res Public Health. 2020;17(2):409.
    1. Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde MW, et al. Pulmonary illness related to e-cigarette use in illinois and Wisconsin—final report. N Engl J Med. 2020;382(10):903–916.
    1. Gallus S, Borroni E, Liu X, Carrozzi L, Dalla Pietra G, Eslami Varzaneh S, et al. Electronic cigarette use among Italian smokers: patterns, settings, and adverse events. Tumori. 2020;26:300891620915784.
    1. Pisinger C, Dagli E, Filippidis FT, Hedman L, Janson C, Loukides S, et al. ERS and tobacco harm reduction. Eur Respir J. 2019;54(6):1902009.
    1. Bourdrel T, Bind MA, Bejot Y, Morel O, Argacha JF. Cardiovascular effects of air pollution. Arch Cardiovasc Diseases. 2017;110(11):634–642.
    1. Giorgini P, Rubenfire M, Das R, Gracik T, Wang L, Morishita M, et al. Particulate matter air pollution and ambient temperature: opposing effects on blood pressure in high-risk cardiac patients. J Hypertens. 2015;33(10):2032–2038.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться